Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health (GH) is a leader in precision oncology, pioneering non-invasive liquid biopsy tests for cancer detection and monitoring. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's financial performance, clinical advancements, and strategic initiatives.
Access authoritative coverage of earnings reports, regulatory milestones, and technology innovations shaping cancer diagnostics. Our curated collection includes press releases on clinical trial results, partnership announcements, and peer-reviewed research developments directly from Guardant Health's communications.
Key updates cover FDA clearances for diagnostic assays, global commercialization efforts, and data partnerships advancing precision medicine. Stay informed about developments in molecular residual disease detection, expanded test indications, and reimbursement progress affecting healthcare adoption.
Bookmark this page for consolidated access to verified information about liquid biopsy advancements and GH's role in transforming cancer care through genomic insights. Check regularly for objective reporting on developments impacting both clinical practice and investment considerations.
Guardant Health (NASDAQ: GH) announced promising data from its investigational Guardant SHIELD multi-cancer assay. This blood test analyzes approximately 20,000 epigenomic biomarkers to detect early-stage cancers, specifically colorectal, lung, pancreatic, and bladder cancers, which account for over 200,000 deaths annually in the U.S. The assay demonstrated a 90% sensitivity for stages I and II colorectal cancer and 87% for lung cancer, with high accuracy in identifying tumor tissue types. These results suggest potential to significantly improve cancer screening rates and save lives.
Guardant Health has announced a partnership with Epic, enhancing access to its cancer tests for over 250 million patients. This integration allows healthcare providers to electronically order Guardant tests, including Guardant SHIELD for colorectal cancer screening, and access results seamlessly. The collaboration aims to simplify workflows for clinicians, improving patient care by ensuring quick access to critical test results. The integration is expected to be completed in Q3 2023, promoting the adoption of Guardant's precision oncology offerings across diverse healthcare settings.
Guardant Health (Nasdaq: GH) responded to a lawsuit from Illumina challenging its ownership of intellectual property related to blood tests. Guardant claims the lawsuit is an attempt to suppress competition, following its concerns about the antitrust implications of Illumina's acquisition of Grail. Despite legal challenges, Guardant remains committed to its mission of developing cancer screening tests. The company maintains that their long-term supply agreement with Illumina is intact and that they will vigorously defend their intellectual property rights.
Guardant Health, Inc. (Nasdaq: GH) has received regulatory approval from the Japanese Ministry of Health, Labour and Welfare for its Guardant360® CDx test, which profiles tumor mutations in patients with advanced solid tumors. The test will identify patients with microsatellite instability-high (MSI-High) tumors eligible for Keytruda® and Opdivo®. This approval enhances the company's commitment to improving cancer care through innovative blood-based diagnostics, following a prior approval for NSCLC in December 2021.
Guardant Health (Nasdaq: GH) announced it will present new findings from its next-generation Guardant SHIELD assay at the AACR Annual Meeting from April 8-13, 2022. The data highlights the assay's ability to detect early-stage cancers and accurately identify their tissue of origin. Co-CEO AmirAli Talasaz emphasized the company's commitment to enhancing cancer care. The presentation will cover various studies, including a highly-sensitive cell-free DNA assay and real-world effectiveness of CDK4/6 inhibitors for breast cancer.
Guardant Health, Inc. (NASDAQ: GH) announced that Palmetto GBA has granted coverage for its Guardant360 TissueNext™ test under the existing local coverage determination for next-generation sequencing of solid tumors. This tissue-based test aims to assist oncologists in identifying advanced cancer patients who may benefit from biomarker-informed treatments. Medicare will cover the test for fee-for-service patients with advanced solid tumor cancers. This marks an expansion of coverage for Guardant's tests and enhances access to genomic profiling for patients with advanced cancer.
Guardant Health reported strong Q4 2021 results with revenue of $108 million, a 38% increase year-over-year. For the full year, revenue reached $374 million, up 30%. Clinical tests surged by 48% to 25,600, while biopharma tests rose 36% to 6,600. Gross profit improved to $74.7 million with a 69% gross margin. Despite increased operating expenses of $172.9 million, the net loss narrowed to $90.9 million. The company expects 2022 revenue between $460 million and $470 million.
Guardant Health, a leading precision oncology company, will participate virtually in several key investor conferences in February and March 2022. The conferences include:
- 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 9:00 a.m. PT.
- Citi 2022 Healthcare Conference on February 24 at 11:45 a.m. PT.
- Cowen 42nd Annual Health Care Conference on March 8 at 10:30 a.m. PT.
Live and archived webcasts will be available on the company's website. Guardant Health aims to enhance cancer care through its innovative tests and analytics.
Guardant Health, Inc. (NASDAQ: GH) announced it will release its financial results for Q4 and the full year 2021 on February 23, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET). The event can be streamed live from the company’s website, with an archive available post-event. Guardant Health specializes in precision oncology, offering advanced diagnostic tests like Guardant360 and Guardant Reveal to enhance cancer care.
Guardant Health (Nasdaq: GH) announced positive data from the interim analysis of the COSMOS-CRC-01 study, showcasing the Guardant Reveal™ liquid biopsy test's efficacy in detecting molecular residual disease in early-stage colorectal cancer. The test can identify disease recurrence with a lead time of over six months post-surgery. Additionally, the Guardant360® test demonstrated comparable detection rates for microsatellite instability-high status in advanced gastrointestinal cancers. These findings will be presented at the 2022 ASCO Gastrointestinal Cancers Symposium from January 20-22, 2022.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
